AmberGen | GenomeWeb


Universidad del Pais Vasco of Leioa-Vizcaya, Spain, has been awarded US Patent No. 8,486,637, "Methods and reagents for the detection of Salmonella spp."

MDxHealth and GlaxoSmithKline Biologicals, both of Belgium, have been awarded US Patent No. 8,481,700, "Detection of MAGE-A expression."
Ilse Vlassenbroeck and Katja Bierau are named as inventors.

Panasonic of Osaka, Japan, has received US Patent Nos.

AmberGen is developing a microbead-based, multiplexed, in vitro pediatric allergy test. The diagnostic is designed to enable the detection of multiple allergen-specific IgE antibodies in blood, according to a company executive.

Microarray-Related NIH Grants, Jan. 1 – May 10, 2012

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use with SomaLogic's Somascan technology platform under a deal announced on Tuesday.

Winners of NCI's Bridge awards, which give up to $3 million to cross the biomedical business 'valley of death', include 20/20 GeneSystems, Ambergen, and Advanced Cell Diagnostics.

Paired Ends


Christopher Sears

Patents of Note


Sequencing-Related US Patents Granted May 20 – June 23

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.